Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • CardieX’s health device division has recorded the highest sales growth in the past five years for the first quarter of the 2020 financial year
  • Sales for the XCEL product ended the first quarter of 2020 at over $900,000
  • The product is designed to better inform health specialists about blood pressure management
  • This news comes a week after CardieX reported a consolidated loss of just over $3 million for the 2019 financial year
  • CardieX shares are up 4.17 per cent today just before market close

CardieX has reported the highest sales growth in the last five years from its ATCOR division for the first quarter of the 2020 financial year.

ATCOR is the medical device arm of CardieX and has reportedly seen sales growth of 88 per cent this quarter compared to the same time last year.

Sales for CardieX’s flagship XCEL product increased by more than $430,000 over the first quarter of the 2019 financial year and ended the first quarter of 2020 at over $900,000.

The XCEL device is a non-invasive central blood pressure assessment tool designed for central arterial waveform analysis.

Essentially, the product better informs health specialists about blood pressure management and helps physicians care for patients with hypertension, renal disease, heart failure, diabetes, and more.

CardieX saw the biggest sales increases come from the U.S. Pharma industry with sales up 132 per cent. Europe and the Middle East followed close behind with sales up 129 per cent for the quarter.

CardieX CEO Craig Cooper said the company is looking forward to building on the strong start to the year.

“As we continue to roll out new pricing, sales, lead generation, and marketing campaigns we are starting to see the results of these efforts in our monthly growth and revenues,” he said.

The high sales are welcome news for the company, who shared with the market last week a consolidated loss of just over $3 million for the 2019 financial year — a loss $500,000 more compared to 2018.

The company is hoping its investment into marketing and sales — which made up $2.1 million worth of expenses in 2019 — will pay off in the future.

In the meantime, CardieX shares are up 4.17 per cent today just before market close. Shares in the medical company are worth 2.5 cents each in a $17.39 million market cap.

CDX by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.